Shares of AxoGen, Inc. (NASDAQ:AXGN) have been given an average recommendation of “Buy” by the ten ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $31.71.
AXGN has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AxoGen in a research report on Friday, January 5th. BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. Jefferies Group initiated coverage on shares of AxoGen in a research report on Thursday, November 30th. They issued a “buy” rating and a $35.00 price objective for the company. Lake Street Capital increased their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 21st. Finally, Leerink Swann increased their price objective on shares of AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, November 21st.
In other AxoGen news, CFO Jamie Mark Grooms sold 10,300 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $26.21, for a total value of $269,963.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 207,812 shares of company stock valued at $5,604,984 in the last ninety days. 9.33% of the stock is owned by corporate insiders.
AxoGen (NASDAQ:AXGN) traded up $2.10 during midday trading on Wednesday, reaching $35.35. 245,413 shares of the company traded hands, compared to its average volume of 330,898. AxoGen has a 52-week low of $9.70 and a 52-week high of $35.40. The company has a debt-to-equity ratio of 0.79, a current ratio of 4.07 and a quick ratio of 3.53. The stock has a market capitalization of $1,147.02, a price-to-earnings ratio of -117.83 and a beta of 0.10.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The firm had revenue of $16.97 million for the quarter, compared to analyst estimates of $16.38 million. During the same quarter last year, the firm posted ($0.10) earnings per share. AxoGen’s revenue for the quarter was up 48.7% compared to the same quarter last year. sell-side analysts anticipate that AxoGen will post -0.28 earnings per share for the current fiscal year.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company?s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.